CTRI/2021/02/031263尚未招募不适用
An Open Label Balanced Randomized Single Dose Four Treatment Four Period Four Sequence Four Way Crossover Study Of Relative Bioavailability Of T1 Curemin Actif Imm capsules 125 Mg Curcuminoids 125 Mg Turmeric Matrix Manufactured By Imm Institut Fuer Mitochondriale Medizin Pfalzburgerstrasse 43/44 10717 Berlin Germany T2 Meriva Thorne Curcumin Phytosome Curcuma Longa Extract Root Phospholipid Complex From Sunflower 500mg Curcumin & Other Curcuminoids 180 Mg Manufactured By Indena s p a Viale Ortles 12 20139 Milano Italy T3 Curcumin Loges capsules Novasol 50.4 Mg Curcuma Extract 35.5 Mg Curcumin Manufactured By DrLoges Co. Gmbh Post Box 1262 Schuetzenstrasse 5 21423 Winsen Luhe Germany T4 Curcumin Intravenous Infusion Burg Apotheke 150 Mg Curcumin Diferuloylmethan Manufactured By Burg Apotheke Koenigstein Frankfurterstrasse 7 16462 Koenigstein Im Taunus Germany In Healthy Adult Human Subjects Under Fed Conditions
Institut fuer mitochondriale Medizin1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2021年2月22日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- To evaluate the Relative Bioavailability Of the test product in healthy, adult, human subjects under fed conditions
研究概览
简要总结
The curcumin exhibits poor bioavailability is well documented. The major reasons attributed to the
low bioavailability of curcumin are poor absorption, rapid metabolism, and rapid systemic
elimination. In humans a comprehensive pharmacokinetic data do not exist.
The systemic elimination of curcumin is another contributing factor for low bioavailability of
curcumin.
Existing evidence in the
literature is insufficient to draw conclusions about the factors controlling the in vivo elimination halflife of curcumin, and future studies are warranted to address this issue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 45.00 Year(s)（—）
- 性别
- All
入选标准
- •Normal, healthy, adult, human subjects of age between 18-45 years with a Body Mass Index (BMI) ranges between 18.50 kg/m2 to 24.99 kg/m2(according to the formula of BMI weight (kg) / [height (m)]2).
- •Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 21 days of check in.
- •Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator to be of no clinical significance.
- •Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
- •Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray and clinical laboratory assessments.
- •Non- smokers or ex-smokers.
- •Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months.
- •Willing to consume standard breakfast.
- •Willing to comply to all requirements of this study protocol as well as instructed by thestudy personnel Generally healthy as documented by gynecological examination and breast examination (for female subjects – period I only).
- •Female subjects within normal limits or clinically non-significant laboratory evaluation results for FSH & LH.
- •Female subjects of childbearing potential; Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or Surgically sterile (bilateral tubal ligation).
排除标准
- •Evidence of allergy or known hypersensitivity to Curcumin or its inactive ingredients.
- •Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus and pre-existing gallbladder disease.
- •Any major illness in the last three months or any significant ongoing chronic medical illness.
- •Renal or liver impairment.
- •Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •History of alcohol addiction or abuse.
- •Consumption of caffeine and /or Xanthine containing products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) tobacco containing products for at least 48.00 hours prior to dosing and throughout the entire study.
- •Consumption of alcohol and its products, grapefruit and/ or its juice and poppy containing foods within 72.00 hours prior to dosing and throughout the entire study.
- •Subjects should not take any over the counter medicinal products, herbal medications within 07 days prior to study check-in and throughout the study and any prescription medications within 14 days prior to study check-in and throughout the study.
- •An unusual or abnormal diet within 48.00 hours prior to dosing of each period, for whatever reason e.g. because of fasting due to religious reasons.
- •Systolic blood pressure less than 90mrn Hg or more than 140mmHg and diastolic blood pressure less than 60 mmHg or more than 90 mmHg. Subject who had participated in any other study within the 90 days of check-in.
- •History of difficulty in swallowing.
- •History of difficulty in accessibility of veins.
- •Positive results for urine screen of drugs of abuse (Marijuana-THC, amphetamine-AMP, barbiturates-BAR, cocaine-COC, benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period.
- •Positive results for alcohol breath test prior to check-in of each period.
- •Any blood donation / excess blood loss within 90 days of check-in.
- •Ingestion of any hormonal agent at any time within 14 days prior to start of study check-in.
- •Use of hormone replacement therapy for a Period of 06 months prior to dosing.
- •Female subjects demonstrating a positive pregnancy screen.
- •Female subjects whose menstruation cycle coincides with the study periods Female subjects who are currently lactating.
- •Females likely to become pregnant during conducting of the study.
结局指标
主要结局
To evaluate the Relative Bioavailability Of the test product in healthy, adult, human subjects under fed conditions
时间窗: 21 days
次要结局
- To monitor the safety and tolerability of a single dose administered in healthy human adult subjects under fed conditions.(21 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult SubjectsHealthy Adult SubjectsNCT05334043The Affiliated Hospital of Qingdao University12
已完成
1 期
Bioavailability of Curcumin Capsules in Healthy Adult SubjectsHealthy Adult SubjectsNCT04972045The Affiliated Hospital of Qingdao University12
已完成
不适用
Enhanced Absorption of curQ+ or Liposomal Curcumin Formulations Versus 95% Curcumin Powder in Healthy SubjectsBioavailabilityNCT06177483ESM Technologies, LLC25
已完成
不适用
Bioavailability of different Curcumin formulations in healthy subjects: a randomized, controlled, cross-over studyDRKS00027929Apomedica Pharmazeutische Produkte GmbH12
已完成
4 期
Bioavailability study of two Curcuminoids formulations of Drishtee Naturals Private Limited, India with two marketed Curcuminoids formulations in 20 Healthy adult human male subjects under fasting conditions.CTRI/2016/02/006604Drishtee Naturals Pvt Ltd20